Heart patients often take up to four medications a day, three times
a day, and that can be overwhelming, said Dr. Karla Santo.
"Our results are really encouraging, especially because the apps
that we used were already freely available in the app stores and
were already being used by millions of people," Santo told Reuters
Health by email.
As reported in the journal Heart, Santo and colleagues at the
University of Sydney in New South Wales randomly divided 150
volunteers with coronary heart disease into three groups. One group
used a basic medication reminder app, a second used an advanced app
with customizable features, and a third group was not given an app.
Before the study, none of the participants had used apps to remind
them to take their pills.

The apps were chosen for the experiment based on an earlier study by
the same researchers in which they ranked medication reminder apps
available in Australia for iOS and Android devices. The top-scoring
free basic app was My Heart, My Life (from the Heart Foundation of
Australia), and the top-scoring free advanced app was Medisafe,
which is available in the U.S. and the UK.
Three months later, patients in each group took a questionnaire
designed to assess medication adherence. Scores showed that
app-users stuck more closely to their pill regimens than patients
who weren't using a reminder app.
The average difference between app-users and non-users was small,
however – only 0.47 points on an 8-point scale. That may have been
because participants generally had medium or high medication
adherence to start with, the researchers suggest.
"Low-adherence" - meaning people largely did not comply with their
schedule - was more common without apps (29 percent, vs 19 percent
among app users).

[to top of second column] |

App users did not seem to get extra benefit from advanced features,
such as the ability to snooze reminders, track doses, provide
adherence statistics and alert a friend or family member to missed
doses.
Heart disease and stroke are the leading causes of death globally,
according to the World Health Organization, and researchers note
about 40 percent of cardiovascular patients worldwide do not abide
by their medication schedule.
"The best way to keep track of medications is to use the tool you
have within reach, and more often than ever, that involves an app,"
said Dr. Karandeep Singh, an assistant professor at the University
of Michigan in Ann Arbor, who was not involved in the study.
Singh, who researches mobile health apps, called the study design
"encouraging." He said a lack of rigorous research has slowed the
uptake of apps into guidelines and clinical practice.
Indeed, Santo's team writes, while there are thousands of health
apps available, there is minimal evidence of their effectiveness in
improving health or medication adherence. Regarding the current
study, they admit their data only reflects a three-month period and
longer-term follow up is needed.

Still, Santo thinks more patients could benefit from reminder apps.
"I think these apps would be useful for any patient that is required
to take long-term medications such as patients with chronic diseases
like diabetes, respiratory disease and HIV/AIDS," she said.
"We could recommend to physicians to start a conversation with their
patients about how well they are taking their medications and
probably suggest the use of a medication reminder app," she added.
SOURCE: http://bit.ly/2Pn7awh Heart, online August 27, 2018.
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |